CO2022004596A2 - Tak-925 para uso en el tratamiento de la narcolepsia - Google Patents
Tak-925 para uso en el tratamiento de la narcolepsiaInfo
- Publication number
- CO2022004596A2 CO2022004596A2 CONC2022/0004596A CO2022004596A CO2022004596A2 CO 2022004596 A2 CO2022004596 A2 CO 2022004596A2 CO 2022004596 A CO2022004596 A CO 2022004596A CO 2022004596 A2 CO2022004596 A2 CO 2022004596A2
- Authority
- CO
- Colombia
- Prior art keywords
- narcolepsy
- compound
- tak
- treatment
- subject
- Prior art date
Links
- 201000003631 narcolepsy Diseases 0.000 title abstract 2
- UXZAJSZFFARTEI-YRPNKDGESA-N CS(=O)(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OC)CO[C@@H]1CC[C@@H](CC1)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N[C@@H]1[C@@H](N(CCC1)C(=O)OC)CO[C@@H]1CC[C@@H](CC1)C1=CC=CC=C1 UXZAJSZFFARTEI-YRPNKDGESA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000035959 Narcolepsy type 1 Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000004461 narcolepsy 1 Diseases 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900298P | 2019-09-13 | 2019-09-13 | |
| US202063031686P | 2020-05-29 | 2020-05-29 | |
| PCT/IB2020/058483 WO2021048822A1 (en) | 2019-09-13 | 2020-09-12 | Tak-925 for use in treating narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022004596A2 true CO2022004596A2 (es) | 2022-08-30 |
Family
ID=72560858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0004596A CO2022004596A2 (es) | 2019-09-13 | 2022-04-11 | Tak-925 para uso en el tratamiento de la narcolepsia |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220339143A1 (https=) |
| EP (1) | EP4028004A1 (https=) |
| JP (1) | JP2022547711A (https=) |
| KR (1) | KR20220062012A (https=) |
| CN (1) | CN114980892A (https=) |
| AU (1) | AU2020346456A1 (https=) |
| BR (1) | BR112022004587A2 (https=) |
| CA (1) | CA3154321A1 (https=) |
| CO (1) | CO2022004596A2 (https=) |
| MX (1) | MX2022003018A (https=) |
| WO (1) | WO2021048822A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022004576A2 (pt) * | 2019-09-13 | 2022-06-14 | Takeda Pharmaceuticals Co | Métodos para diminuir ou tratar sonolência excessiva, tratar narcolepsia tipo 2 ou hipersonia idiopática, tratar distúrbio de trabalho de turno, aumentar latência de sono em manutenção de teste de insônia, melhorar classificação de escaça de sonolência de karolinska, diminuir ou melhorar sonolência subjetiva, aumentar insônia ou diminuir sonolência excessiva, melhorar classificação de escala de sonolência epworth, tratar narcolepsia tipo 2, diminuir ou tratar sonolência diurna excessiva, e, composição farmacêutica |
| MX2022008392A (es) | 2020-01-10 | 2022-08-08 | Takeda Pharmaceuticals Co | Metodo para mejorar la farmacocinetica o aumentar la concentracion de plasma de 3-((metilsulfonil)amino)-2-(((4-fenilci clohexil)oxi)metil)piperidina-1-carboxilato de metilo o una sal del mismo con un inhibidor de citocromo p450. |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| BR112023020104A2 (pt) * | 2021-04-02 | 2023-11-14 | Takeda Pharmaceuticals Co | Métodos para recuperação pós-operação, para facilitar a recuperação ou reduzir o tempo de recuperação da anestesia, para prevenir ou tratar distúrbios/depressão respiratória pós-operatória ou distúrbios/depressão respiratória induzida por opioides, sedação pós-operatória ou sedação induzida por opioides e para reduzir um efeito colateral de opioides |
| CN119677753A (zh) | 2022-04-22 | 2025-03-21 | 帝人制药株式会社 | 氧杂氮杂环庚三烯衍生物 |
| AR130709A1 (es) | 2022-10-07 | 2025-01-08 | Kissei Pharmaceutical | Compuesto de ciclopentano |
| WO2024095158A1 (en) * | 2022-10-31 | 2024-05-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| TW202535890A (zh) | 2023-10-20 | 2025-09-16 | 日商帝人製藥股份有限公司 | 氧氮呯衍生物之結晶或其溶劑合物之結晶 |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025229493A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854204A (en) | 1995-03-14 | 1998-12-29 | Praecis Pharmaceuticals, Inc. | Aβ peptides that modulate β-amyloid aggregation |
| JP2001500852A (ja) | 1996-08-27 | 2001-01-23 | プレーシス ファーマスーティカルズ インコーポレイテッド | Ｄ―アミノ酸を含むβ―アミロイドペプチド凝集のモジュレーター |
| CA2374610A1 (en) | 1999-06-28 | 2001-01-04 | Jordan J. N. Tang | Catalytically active recombinant memapsin and methods of use thereof |
| ES2843952T3 (es) * | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| US10022355B2 (en) * | 2015-06-12 | 2018-07-17 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder |
| PL3411358T3 (pl) * | 2016-02-04 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Podstawiony związek piperydynowy i jego zastosowanie |
-
2020
- 2020-09-12 CA CA3154321A patent/CA3154321A1/en active Pending
- 2020-09-12 JP JP2022516270A patent/JP2022547711A/ja active Pending
- 2020-09-12 WO PCT/IB2020/058483 patent/WO2021048822A1/en not_active Ceased
- 2020-09-12 CN CN202080073637.7A patent/CN114980892A/zh active Pending
- 2020-09-12 BR BR112022004587A patent/BR112022004587A2/pt unknown
- 2020-09-12 AU AU2020346456A patent/AU2020346456A1/en not_active Abandoned
- 2020-09-12 KR KR1020227011013A patent/KR20220062012A/ko active Pending
- 2020-09-12 EP EP20775077.9A patent/EP4028004A1/en not_active Withdrawn
- 2020-09-12 MX MX2022003018A patent/MX2022003018A/es unknown
- 2020-09-12 US US17/642,331 patent/US20220339143A1/en not_active Abandoned
-
2022
- 2022-04-11 CO CONC2022/0004596A patent/CO2022004596A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022004587A2 (pt) | 2022-06-14 |
| KR20220062012A (ko) | 2022-05-13 |
| CN114980892A (zh) | 2022-08-30 |
| US20220339143A1 (en) | 2022-10-27 |
| WO2021048822A1 (en) | 2021-03-18 |
| AU2020346456A1 (en) | 2022-04-14 |
| CA3154321A1 (en) | 2021-03-18 |
| EP4028004A1 (en) | 2022-07-20 |
| MX2022003018A (es) | 2022-06-14 |
| JP2022547711A (ja) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022004596A2 (es) | Tak-925 para uso en el tratamiento de la narcolepsia | |
| MX2024003960A (es) | Compuestos antivirales que contienen nitrilo. | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| UY28674A1 (es) | Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1 | |
| UY38483A (es) | Heterociclos funcionalizados como agentes antivirales | |
| CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
| CL2008001194A1 (es) | Composicion farmaceutica que comprende florfenico, una ciclodextrina y agua, un solvente y7o una mezcka de los mismos, con al menos 5% de solvente; kit que la contiene; complejo de florfenicol, util para tratr enfermedades respiratorias en animales | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| AR060089A1 (es) | Tratamiento del dolor | |
| AR119479A1 (es) | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer | |
| BR0309343A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas | |
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| PE20211595A1 (es) | Compuestos de 2,6-diaminopiridina | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| MX2025003008A (es) | Regimen de dosificacion para el tratamiento de la pku con un inhibidor de la funcion de slc6a19 como piperidina | |
| CL2024002763A1 (es) | Dosificación no lineal de mirdametinib | |
| CL2022001353A1 (es) | Inhibidores de egfr | |
| BR112022013547A2 (pt) | Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição | |
| CO2022008690A2 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| PE20060364A1 (es) | Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
| CO2025016753A2 (es) | Inhibidores de gsk3α y métodos de uso de estos | |
| PE20241186A1 (es) | Compuestos de cd73 |